ArticleBMC neurology2024

Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study.

Melika Jameie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.